Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Co-administration of Arexvy and Comirnaty Omicron XBB.1.5 in Adults ≥50 Years
2023-510196-59-00Phase 3Completed
- Sponsor
- GSK
- Start
- Jun 2024
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 4
01
Overview
Phase 3, randomised, open-label trial of GSK3003899A and raxtozinameran in respiratory syncytial virus disease (RSV) and coronavirus disease 2019 (COVID-19) (2 arms), sponsored by GSK. Started Jun 2024; status: completed.
02
Drugs
GSK3003899Araxtozinameran
03
Conditions
respiratory syncytial virus disease (RSV)coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2023-510196-59-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-510196-59-00.